International prescribing practices in obsessive-compulsive disorder (OCD)
No Thumbnail Available
Date
2016
Authors
Brakoulias, Vlasios
Starcevic, Vladan
Belloch, Amparo
Dell'Osso, Liliana
Ferrao, Ygor A.
Fontenelle, Leonardo F.
Lochner, Christine
Marazziti, Donatella
Martin, Andrew
Matsunaga, Hisato
relationships.isAdvisorOf
item.page.type-of
Artigo
Journal Title
Journal ISSN
Volume Title
Abstract
ObjectivesTo assess rates of psychotropic medication use in patients with obsessive-compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines. MethodsResearchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated. ResultsThe data came from Brazil (n=955), Italy (n=750), South Africa (n=555), Japan (n=382), Australia (n=213), India (n=202) and Spain (n=82). The majority (77.9%
n=2445) of the total sample of 3139 participants received a psychotropic medication. Consistent with international guidelines, selective serotonin reuptake inhibitors (SSRIs) were most commonly used (73.5%, n=1796), but their use ranged from 59% in Australia to 96% in Japan. Clomipramine use varied from 5% in Japan and South Africa to 26% in India and Italy. Atypical antipsychotic use ranged from 12% in South Africa to 50% in Japan. ConclusionsPharmacotherapy for OCD varied significantly across sites. Prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that may play a role in the variation in prescribing practices internationally and whether these variations influence treatment outcomes. Copyright (c) 2016 John Wiley & Sons, Ltd.
n=2445) of the total sample of 3139 participants received a psychotropic medication. Consistent with international guidelines, selective serotonin reuptake inhibitors (SSRIs) were most commonly used (73.5%, n=1796), but their use ranged from 59% in Australia to 96% in Japan. Clomipramine use varied from 5% in Japan and South Africa to 26% in India and Italy. Atypical antipsychotic use ranged from 12% in South Africa to 50% in Japan. ConclusionsPharmacotherapy for OCD varied significantly across sites. Prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that may play a role in the variation in prescribing practices internationally and whether these variations influence treatment outcomes. Copyright (c) 2016 John Wiley & Sons, Ltd.
Description
Citation
Human Psychopharmacology-Clinical And Experimental. Hoboken, v. 31, n. 4, p. 319-324, 2016.